Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply.
Saved in:
| Title: | Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply. |
|---|---|
| Authors: | Subbiah V; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: vsubbiah@mdanderson.org., Lassen U; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Gasal E; Global Drug Development, Novartis Pharmaceuticals, East Hanover, NJ, USA., Burgess P; Global Drug Development, Novartis Pharma, Basel, Switzerland., Wainberg ZA; Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA. |
| Source: | The Lancet. Oncology [Lancet Oncol] 2020 Nov; Vol. 21 (11), pp. e516. |
| Publication Type: | Letter; Comment |
| Journal Info: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1474-5488 |
|---|---|
| DOI: | 10.1016/S1470-2045(20)30625-2 |
